Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumours and Titrated in Combination Therapy With Temodar for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas.

Trial Profile

A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumours and Titrated in Combination Therapy With Temodar for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboxyamidotriazole orotate (Primary) ; Temozolomide
  • Indications Glioblastoma; Glioma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Tactical Therapeutics
  • Most Recent Events

    • 20 Sep 2023 Planned primary completion date changed from 1 Jun 2018 to 1 Jan 2024.
    • 23 Apr 2018 Results published in the Journal of Clinical Oncology.
    • 07 Jun 2016 Results ((n=15) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top